From Chief Investment Officer Tom Veale, Stock price recovery has continued to outpace earnings increases so far. This puts upward pressure on Price to Earnings ratios and therefore a rising risk posture for our SignalPoint Relative Valuation Index. Valuations relative to the “risk free rate of return” deteriorated this week with both a rise in […]
From Chief Investment Officer Tom Veale, “While the SignalPoint Market Risk Indicator didn’t rise this week one key component, Relative Valuation, did. Rising market prices without rising income tends to push this key risk measure upward. Here’s how the MRI looks for November 21st, 2022.
From Chief Investment Officer “Another unusual week passed while market indexes rose, overall. SignalPoint’s Market Risk Indicator (MRI) rose slightly in concert with the markets. A quick review of our Domestic Sector ETF strategy (Signal 10) finds 8 out of the 11 positions are now back above their 26 Week Moving Average share prices. Most […]
From Chief Investment Officer Tom Veale, “The unfortunate thing about watching markets recover is the dilutive aspects of fundamentals deteriorating with that recovery. If indexes rise with no improvement in earnings, we see Price to Earnings becoming more risky. If investors are not convinced of a change in market trend we see large numbers of […]
From Chief Investment Officer Tom Veale, “Investors are feeling confused with market action in recent weeks. Yes, markets are rising but investors are yet to embrace this action as being a long term trend. SignalPoint’s MRI Divergence Index shows this poor consensus with a rise well above its median value. Our MRI rose one point […]
From Chief Investment Officer Tom Veale, “An uptick in the Indexes looked pretty good at Friday’s close. However, reviewing where they were a year ago does give a different perspective. Were they “too high” back then? Are they “too low” now?
Fact Sheet – Universal Signal – Q3 2022
Fact Sheet – Stable Income – Q3 2022
Fact Sheet – Global Signal – Q3 2022
Fact Sheet – Signal 10 – Q3 2022